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Adipose tissue hyaluronan production improves
systemic glucose homeostasis and primes
adipocytes for CL 316,243-stimulated lipolysis
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Plasma hyaluronan (HA) increases systemically in type 2 diabetes (T2D) and the HA
synthesis inhibitor, 4-Methylumbelliferone, has been proposed to treat the disease. However,
HA is also implicated in normal physiology. Therefore, we generated a Hyaluronan Synthase
2 transgenic mouse line, driven by a tet-response element promoter to understand the role of
HA in systemic metabolism. To our surprise, adipocyte-specific overproduction of HA leads
to smaller adipocytes and protects mice from high-fat-high-sucrose-diet-induced obesity and
glucose intolerance. Adipocytes also have more free glycerol that can be released upon beta3
adrenergic stimulation. Improvements in glucose tolerance were not linked to increased
plasma HA. Instead, an HA-driven systemic substrate redistribution and adipose tissue-liver
crosstalk contributes to the systemic glucose improvements. In summary, we demonstrate an
unexpected improvement in glucose metabolism as a consequence of HA overproduction in
adipose tissue, which argues against the use of systemic HA synthesis inhibitors to treat
obesity and T2D.
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The extracellular matrix (ECM) is a three-dimensionalnetwork composed of collagens, enzymes, and glycopro-teins that provide structural and biophysical support for
cells1,2. Non-sulfated glycosaminoglycans, such as hyaluronic
acids (HA), are important components of the ECM as well. HA is
a polysaccharide with simple linear repeating disaccharide units
of D-glucuronic acid (GlcUA) and N-acetyl-D-glucosamine
(GlcNAc)3,4, synthesized by hyaluronan synthases5 and broken
down by hyaluronidases or via non-enzymatic degradation by
reactive oxygen species6.
Glucose is the starting point of HA synthesis: cytosolic UDP-
GlcUA and UDP-GlcNA, produced by side reactions of the gly-
colytic pathway, are used by hyaluronan synthases to produce
HA. Accumulation of HA has been observed in both type 1 and
type 2 diabetes and chronic liver diseases, either locally or sys-
temically. Peri-islet HA deposition is associated with the loss of
immune-tolerance and development of insulitis in type 1 diabetes
(T1D)7. Increased plasma HA levels are also associated with type
2 diabetes and liver cirrhosis8–10. Thus, HA has been implicated
as a causal factor for many metabolic diseases11.
On the other hand, HA plays important roles in many aspects
of normal physiology. For example, it has a high abundance in
dermal tissues and is crucial in retaining water content in the skin
due to its extreme hydrophilicity12. HA is also crucial for joint
health, acting as a natural lubricant for joints13,14. Recently, a HA
constituted perineuronal net has been implicated in neuronal
maturation15. HA injections have been approved for the treat-
ment of knee pain caused by osteoarthritis in patients16. All these
beneficial aspects of HA prompt many individuals to take HA as
nutritional supplements or look for other ways to increase sys-
temic HA levels.
Here, we started with the observations that metabolically
unhealthy individuals with obesity and prediabetes have higher
basal and postprandial circulating HA levels than people who are
obese, but who are metabolically healthy and with normal oral
glucose tolerance. To understand whether circulating HA levels
directly drive metabolic dysfunction, we have used transgenic
mouse models with altered HA levels in various tissues and in
circulation. Contrary to our expectations, adipose tissue HA
production significantly improved systemic glucose tolerance. We
excluded the possibility that increased circulating HA that leaks
from Has2 overexpressing adipose tissue is responsible for the
improvement in systemic glucose metabolism by using two other
experimental models with elevated circulating HA. We deter-
mined that HA primes adipocytes for lipolysis, resulting in
smaller adipocytes and overall lower body weight and lower fat
mass upon a metabolic challenge. HA-driven lipolysis and
decreases in lipid content are cell-autonomous phenomena,
which can be replicated in vitro differentiated adipocytes, and in
hepatocytes in vivo. Furthermore, assaying tissue HA levels raises
some doubts regarding the effectiveness of 4-
Methylumbelliferone (4-MU) to inhibit HA synthesis in vivo.
Overall, we conclude that adipose tissue HA production exerts
beneficial effects on adipose tissue and improves whole-body
metabolic function.
Results
Circulating HA inversely correlates with metabolic health. We
evaluated plasma HA concentrations before and for 5 h after
ingesting a standard meal (50% carbohydrate, 35% fat, 15%
protein) containing one-third of their estimated energy
requirements17 in people with obesity and prediabetes (“Obese-
prediabetes”) and those with obesity and normal oral glucose
tolerance (“Obese-normal)”, who were all matched for body mass
index and percent body fat. Obese-prediabetic cohort has greater
plasma glucose, insulin, HbA1C and triglyceride concentrations,
an index of insulin resistance (homeostasis model of insulin
resistance [HOMA-IR])18, and intrahepatic triglyceride content,
and lower plasma HDL-cholesterol concentrations than in the
Obese-normal group (Table 1). Both basal HA concentrations,
postprandial plasma HA concentrations and plasma HA area
under the curve (AUC) were greater in the Obese-prediabetic
group than the Obese-normal group (Fig. 1A). In addition, basal
plasma HA concentrations were directly correlated with basal
plasma glucose concentrations (Fig. 1B). These data demonstrate
an inverse relationship between plasma HA concentrations and
metabolic health and implicate circulating HA as a possible
causative factor for metabolic dysfunction. However, the obser-
vational design of this study cannot determine cause-and-effect
relationships. HA levels fluctuate during the day and rapidly
increase after a meal, possibly due to vasodilatation and increases
in intestinal lymph flow that displace HA from gastrointestinal
tissues19,20.
High-dose 4-methylumbelliferone (4-MU) treatment improves
glucose tolerance independent of HA inhibition. To test whe-
ther elevated HA levels cause impaired metabolic homeostasis, 4-
MU was used to inhibit HA production (Fig. 2A)21–23. Treatment
of a cohort of obese mice fed with a high-fat/high-sucrose
(HFHS) diet for 20 weeks, with subsequent exposure to 5 weeks of
HFHS diet containing 4-MU, significantly reduced body weight
(Fig. 2B). The treatment also significantly improved glucose tol-
erance (Fig. 2C) and reduced fasting insulin levels by more than
90% (Fig. 2D). Hepatic triglyceride accumulation was reduced
after the treatment (Fig. 2E). Serum alanine transaminase activity
was reduced (Fig. 2F), suggesting a potent protective effect of 4-
MU treatment on the liver. Serum lipid profiles were also vastly
improved: direct high-density lipoprotein (dHDL) and total
cholesterol levels were significantly reduced (Fig. 2G).
A drawback of 4-MU treatment is that it has to be used at very
high doses (5% by weight supplemented in diet)24,25 and it
suppresses food intake at the beginning of the treatment
(Supplementary Fig. 1A)25. Therefore, a pair-fed group was
introduced in the second 4-MU treatment experiment ((Fig. 2H).
After 1 week of 4-MU treatment, there was an average of 15.3%
weight loss in 4-MU treated mice, and pair feeding led to a
similar degree of weight loss (Supplementary Fig. 1B). Similar to
the 5-week treatment, 1-week 4-MU exposure reduced serum









37.9 ± 1.2 39.1 ± 1.3 0.50
Body fat (%) 47.7 ± 1.4 47.7 ± 1.4 0.99
IHTG content (%) 1.7 ± 0.1 16.6 ± 2.5 <0.01
Glucose (mg/dL) 87 ± 1 101 ± 3 <0.01
Insulin (µU/mL) 13 ± 2 27 ± 3 <0.01
HOMA-IR 2.9 ± 0.4 7.0 ± 1.0 <0.01
HbA1C (%) 5.0 ± 0.1 5.7 ± 0.2 <0.01
Triglyceride (mg/dL) 78 ± 7 132 ± 18 <0.01
HDL-cholesterol
(mg/dL)
55 ± 4 43 ± 3 0.01
LDL-cholesterol
(mg/dL)
91 ± 6 108 ± 6 0.08
Data are expressed as mean ± SEM. Two-tailed t-test.
HbA1C hemoglobin A1C, IHTG intrahepatic triglyceride, HOMA-IR homeostasis model
assessment of insulin resistance, Obese-Nl obese with normal oral glucose tolerance, Obese-PD
obese with prediabetes.
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dHDL and cholesterol, and a similar level of improvement was
observed in the pair-fed group (Fig. 2I). Triglycerides and NEFA
were not drastically different (Fig. 2I). 4-MU significantly
increased hepatic triglyceride content compared to HFHS
controls (Fig. 2J), possibly an effect of fasting resulting from
reduced food intake. Surprisingly, 4-MU significantly increased
circulating HA when compared to HFHS controls (Fig. 2K).
Upon reducing the content of 4-MU in HFHS diet to 0.1% (1
gram 4-MU per kg of diet), during a 3-week treatment regimen
(Fig. 2L), mice consumed the same amount of 4-MU diet
(Supplementary Fig. 1C), did not lose weight (Supplementary
Fig. 1D) and there was no improvement in glucose tolerance
(Supplementary Fig. 1E).
Surprisingly, 5% 4-MU also failed to reduce HA content in two
different white adipose tissue depots, and increased HA content
in the brown adipose tissue (Fig. 2M). Intestinal HA was
significantly reduced by 5% 4-MU treatment (Fig. 2M). Liver had
much lower (less than 1% compared to intestine) tissue HA, and
the level was not affected by 4-MU treatment (Fig. 2M). As seen
in pair-fed experiment, 5% 4-MU significantly increased serum
HA levels (Fig. 2N) and had no effect on Has2 expression in the
inguinal adipose tissue (Fig. 2O).
Has2 overexpression increases high-molecular-weight (HMW)
HA. Owing to the complex nature of the high-dose 4-MU
treatment, and the surprising observation that it failed to reduce
adipose tissue HA levels, but rather lead to an unexpected
increase in circulating HA levels, we decided to develop genetic
models to understand the role of HA in systemic metabolism
in vivo.
Based on the endogenous expression pattern, we chose to
overexpress the most abundant adipose tissue hyaluronic acid
synthase (Has) isoform, Has2, to increase HA levels (Fig. 3A and
Supplementary Fig. 2A). The mouse cDNA encoding the ORF for
the Has2 gene was subcloned under the control of a tetracycline
response element (TRE) promoter to make a TRE-Has2
construct. In HEK293 cells with stable rtTA overexpression,
Has2 overexpression increased HA concentrations in the super-
natant by more than threefold with 0.5 µg/mL doxycycline in the
medium (Fig. 3B), reflecting that overexpression of a single HA
synthase in mammalian cells is sufficient to promote HA
production. Met1 mammary tumor cells stably transfected with
CMV-rtTA and TRE-Has2 construct also displayed increased
extracellular space after 24-h 0.5 µg/mL doxycycline treatment
(Fig. 3C). We generated TRE-Has2 transgenic mice by injecting
the linearized TRE-Has2 construct into the pronuclear region of
fertilized oocytes. Founders were crossed to adiponectin-rtTA
(Apn-rtTA) mice26 for screening (Fig. 3D). A line that displays
robust doxycycline-induced transgene expression with minimal
levels of transgene leakage was chosen for further analysis
(Supplementary Fig. 2B). Transgenic overexpression leads to a
significant increase in adipose tissue HAS2 protein (Supplemen-
tary Fig. 2C). After 5 days of transgene induction on 600 mg/kg
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Fig. 1 Circulating HA inversely correlates with metabolic fitness in the human. A Obese-prediabetes (Obese-prediabetes; n= 15 patients) patients have
higher levels of circulating HA compared to obese-normal (Obese-normal; n= 15 patients) patients. Subjects ingested a mixed meal at the indicated time
point. Mean ± s.e.m; For AUC, two-tailed t-test, p= 0.0499. *indicates p≤ 0.05. B Plasma HA concentrations (t= 0’) were directly correlated with basal
plasma glucose concentrations. Logarithmic regression analysis was used to determine the line of best fit to the data.
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increase in alcian blue staining, reflecting an increase of acidic
polysaccharides in adipose tissue (Fig. 3E). Adipose tissue Has2
overexpression increased tissue HA levels by approximately 10-
fold (Fig. 3F). Adipose tissue-derived HA also entered circulation,
leading to a 45% increase in circulating HA levels (Fig. 3G).
Electrophoresis of extracted HA from Has2 overexpressing
adipose tissue demonstrated that HAS2 mainly drove the
production of very high molecular weight HA, with a molecular
weight close to 6000 kDa (Fig. 3H).
Has2 overexpressing white adipocytes also display a morphol-
ogy of multilocular lipid droplets (Fig. 3E), but this is
independent of higher uncoupling protein 1 (Ucp1) expression
(Fig. 3I). Brown adipose tissue Ucp1 expression was not different
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mitochondrial creatine kinases Ckmt2 is drastically increased in
about half of mice (Supplementary Fig. 2E). Genes in other
UCP1-independent thermogenesis processes, such as Atp2a2 in
calcium cycling and Pm20d1 in n-acyl amino acid metabolism,
did not changed (Supplementary Fig. 2F). Cytokine Gdf15
expression was not different, while Fgf21 expression was
significantly decreased (Supplementary Fig. 2G). There was no
change in collagen gene expression levels (Fig. 3I) but a decrease
in genes involved in adipogenesis was apparent (Supplementary
Fig. 2H). Metabolically, 5-day Has2 overexpression in adipocytes
has no effect on body weight (Supplementary Fig. 2I) or glucose
tolerance (Supplementary Fig. 2J).
Adipose Tissue Has2 overexpression improves glucose toler-
ance on an HFHS diet. The effect of HA on systemic glucose
metabolism was first tested in mice with whole-body Has2 (w-
Has2 TG) overexpression driven by R26-M2rtTA. After
doxycycline-induced transgene expression (10 mg/kg in diet) and
metabolic challenge by HFHS diet for 8 weeks, mice displayed a
9.5% lower body weight despite the same body weight at the
starting point of the study (Supplementary Fig. 3A), and also
showed an improved glucose tolerance (Supplementary Fig. 3B).
Subsequently, a more in-depth metabolic characterization was
carried out on adipose tissue-specific Has2 overexpression mice
(Apn-rtTA X TRE-Has2, abbreviated as Apn-Has2) mice
(Fig. 4A). On Dox600 HFHS diet, body weight diverges early on:
two weeks after initiation of diet treatment, Apn-Has2mice weigh
5.4% less, subsequently, the difference further expands to 7.3%
after four weeks; after 16 weeks of an HFHS diet challenge, Apn-
Has2 mice are 11.7% lighter than the control mice on the same
diet (Fig. 4B). Body composition measurements performed
7 weeks after initiation of dietary treatment revealed a 34.8%
reduction in fat mass, with the same lean mass in Apn-Has2 mice
(Fig. 4C). When normalized to body weight, lean mass was in fact
marginally increased (Supplementary Fig. 3C). Despite a reduc-
tion in expression of adipogenesis genes after 5 days of transgene
induction, there was no difference in the PDGFRβ+ progenitor
pool in the stromal vascular fraction of Apn-Has2 mice fed with
Dox600 HFHS diet for 8 weeks (Supplementary Fig. 3D). Mice
with matched body weights were selected and used for a
metabolic cage study. The results show similar levels of food
intake, activity, energy expenditure and RER in Apn-Has2mice at
room temperature (Fig. 4D and Supplementary Fig. 3E). How-
ever, when mice were exposed to a 6-h period in a cold envir-
onment (6 °C), Apn-Has2 mice demonstrated enhance heat
production (Fig. 4D).
Glucose tolerance was significantly improved in Apn-Has2
mice after 8 weeks of dietary treatment (Fig. 4E). The
improvements in glucose tolerance did not come from additional
glucose uptake into the adipose tissue. In fact, 2-deoxyglucose (2-
DG) uptake was significantly blunted in the inguinal fat depots
(Fig. 4F). Similar trends were observed for the epididymal depot,
whereas muscle glucose uptake was unaffected (Fig. 4F). These
differences could also not be explained by circulating insulin
levels (Supplementary Fig. 3F). In vitro differentiated adipocytes
overexpressing Has2 also displayed an impaired insulin-
stimulated 2-DG uptake (Fig. 4G). Insulin tolerance tests reflect
no improvements in peripheral insulin sensitivity in Apn-Has2
mice (Fig. 4H). In contrast, pyruvate tolerance tests (which reflect
hepatic gluconeogenesis), were slightly improved in Apn-Has2
mice (Fig. 4I), suggesting a contribution of improved hepatic
gluconeogenesis to improved whole-body glucose metabolism.
Terminal analysis after 16 weeks of Dox600 HFHS treatment
revealed Apn-Has2 adipocytes were significantly smaller (Fig. 4J),
hepatic triglyceride content was significantly lower (Fig. 4J, K),
with no differences in serum ALT/AST (Supplementary Fig. 3G).
Apn-Has2 mice had an improved HOMA-IR score that was
mostly contributed by reduced fasting insulin (Fig. 4L), while
circulating adiponectin levels remained unchanged (Supplemen-
tary Fig. 3H).
HA injection only marginally improves glucose tolerance in
diet-induced obese mice. Apn-Has2 mice also have increased
circulating HA levels, likely due to the release of HA from the
enlarged adipose tissue HA pool. To understand whether circu-
lating HA has a direct effect on other organs to improve glucose
tolerance, we injected mice with HA intraperitoneally (i.p.) (50
mg/kg body weight) to increase circulating HA levels (Fig. 5A).
An oral gavage of HA at the same dose failed to affect plasma HA
levels (Supplementary Fig. 4A). Four hours after the injection,
Fig. 2 4-MU treatment on HA levels, glucose, and lipid metabolism. A Schematic representation of mouse treatment for panels B–G. B Body weight after
5 weeks of 4-MU HFHS treatment (n= 7 mice for HFHS, n= 6 mice for 4-MU HFHS treatment group). Two-way ANOVA followed by Sidak’s multiple
comparisons test, adjusted p-value= 0.7473, 0.0006, <0.0001, <0.0001 for start, 1 week, 3 weeks and 5 weeks, respectively. C Glucose tolerance after
3 weeks of 4-MU HFHS treatment (n= 7 mice for HFHS, n= 6 mice for 4-MU HFHS treatment group). Two-way ANOVA followed by Sidak’s multiple
comparisons test, adjusted p-value= 0.0646, 0.0084, <0.0001, 0.0001, 0.238 for 0, 15, 30, 60, and 120min, respectively. D Fasting insulin levels after
5 weeks of 4-MU HFHS treatment (n= 7 mice for HFHS, n= 6 mice for 4-MU HFHS treatment group). Two-tailed t-test, p < 0.0001. E Representative
pictures of hepatic lipid accumulation. Scale bar= 100 μm. F Serum AST and ALT enzymatic activity after 5 weeks of 4-MU treatment (n= 7 mice for
HFHS, n= 5 mice for 4-MU HFHS treatment group). Two-tailed t-test, p= 0.2547 and 0.0006 for AST and ALT, respectively. G Serum dHDL, Cholesterol,
Triglyceride and NEFA levels after 5 weeks of 4-MU HFHS treatment (n= 7 mice for HFHS, n= 5 mice for 4-MU HFHS treatment group). Two-tailed t-test,
p= 0.0002, 0.0005, 0.2057, 0.0691 for dHDL, Cholesterol, Triglyceride and NEFA, respectively. H Schematic representation of mouse treatment for
panels I–K. The average amount of food eaten by mice on day “N” in ad libitum 4-MU HFHS feeding group will be given to pair-fed group on day “N+ 1”. I
Serum dHDL, Cholesterol, Triglycerides and NEFA levels (n= 6 mice for HFHS, n= 4 mice for HFHS PF, n= 8 mice for 4-MU treatment group). One-way
ANOVA followed by Tukey’s multiple comparisons test. p-values are reported on the graph. J Hepatic triglyceride content (n= 6 mice for HFHS, n= 6
mice for HFHS PF, n= 8 mice for 4-MU treatment group). One-way ANOVA followed by Tukey’s multiple comparisons test. Adjusted p= 0.0014 for
HFHS vs. 4-MU, adjusted p= 0.0139 for HFHS PF vs. 4-MU. K Serum HA levels (n= 5 mice for HFHS, n= 4 mice for HFHS PF, n= 8 mice for 4-MU
treatment group). One-way ANOVA followed by Tukey’s multiple comparisons test. Adjusted p= 0.0131 for HFHS vs. 4-MU, adjusted p= 0.0851 for
HFHS PF vs. 4-MU. L Schematic representation of mouse treatment for panels M–O. Multiple cohorts of mice were used. M Tissue HA levels from mice
treated with 5% 4-MU in diet. iWAT: inguinal adipose tissue, eWAT: epididymal adipose tissue, BAT: brown adipose tissue (n= 6 mice for each group).
Intestines and livers were harvested from a different cohort of mice undergoing the same treatment (n= 4 mice for vehicle treatment, n= 6 mice for 5% 4-
MU treatment). Two-tailed t-test. N Serum HA levels from mice treated with 0.2% or 5% 4-MU HFHS (n= 8 mice for each group). One-way ANOVA
followed by Tukey’s multiple comparisons test. O Adipose tissue Has2 expression from mice treated with 0.2% or 5% 4-MU HFHS (n= 6 mice for control
group, n= 7 mice for 0.2% 4-MU and 5% 4-MU). One-way ANOVA followed by Tukey’s multiple comparisons test. All data are presented as mean ± s.e.
m. *indicates p≤ 0.05, **indicates p≤ 0.01.
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circulating HA levels were increased five-fold (Fig. 5B), but nei-
ther glucose tolerance (Fig. 5C) nor glucose-stimulated insulin
secretion during the oral glucose tolerance test were different
(Fig. 5D). This indicates that an acute increase in circulating HA
does not modulate glucose homeostasis in a positive way.
We subsequently treated mice that were fed with an HFHS diet
concurrently with the HA i.p. treatment on every second day for
4 weeks (Fig. 5E), which elevated circulating HA levels by at least
50% between two injections (Supplementary Fig. 4B). HA
treatment had no effect on weight gain after 4 weeks (Supple-
mentary Fig. 4C), nor did it affect food uptake (Supplementary
Fig. 4D). Even three weeks of HA treatment only marginally
improved glucose tolerance (Fig. 5F), with no differences in
insulin levels 15 min post the oral glucose administration
A B C
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Fig. 3 Has2 overexpression increases HMW HA. A Has1, Has2, and Has3 expression levels in the adipose tissue from 16-week-old C57BL/6J mice fed with
normal chow diet (n= 4). One-way ANOVA followed by Tukey’s multiple comparisons test. B HEK293 cells overexpressing Has2 increase medium HA
levels (n= 3). Two-tailed t-test to compare rtTA+mCherry+Dox vs. rtTA+Has2+Dox, p < 0.0001. C Representative picture showing Met1 cells
overexpressing Has2 have increased extracellular space revealed by adding mouse red blood cells into the culture before the microscopic imaging. Blue line
indicates the cell’s body, red line indicates the boundary of cell’s extracellular matrix. The space between two lines is the extracellular matrix. Scale bar=
50 µm. D Schematic of mouse cross to generate adipose tissue-specific doxycycline-inducible Has2 overexpressing mice (Apn-Has2). E Representative
pictures of inguinal adipose tissue slides stained with Alcian blue (Scale Bar= 50 µm). Mice were treated with Dox600 chow diet for 5 days. F Tissue HA
concentration after adipose tissue Has2 overexpression induced by Dox600 chow diet treatment for 5 days (n= 5 for control, n= 6 for Apn-Has2
transgenic mice). Two-tailed t-test, p= 0.0019. G Serum HA concentration after adipose tissue Has2 overexpression induced by Dox600 chow diet
treatment for 5 days (n= 4). Two-tailed t-test, p= 0.0032. H Electrophoresis of HA extracted from control and Apn-Has2 mice treated by Dox600 chow
diet for 5 days, demonstrating Has2 overexpression mainly increases very high molecular weight HA. I Gene expression in adipose tissue overexpressing
Has2 after 5 days of Dox600 chow diet treatment (n= 4 for control, n= 6 for Apn-Has2 mice). Two samples were not detected for Aqp7 gene. Two-tailed
t-test for each gene. All data are presented as mean ± s.e.m. **indicates p≤ 0.01.
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(Fig. 5G). Pyruvate tolerance tests did not differ between the HA
treatment group and the PBS control group (Fig. 5H). The insulin
tolerance test revealed a mild impairment in peripheral insulin
sensitivity (Fig. 5I). Altogether this reflects a marginal effect of
systemic HA treatment on glucose homeostasis and can’t account
for metabolic improvement seen in Apn-Has2 mice.
Increasing circulating HA by hepatic Has2 overexpression does
not improve glucose tolerance. Injection of HA may cause a
significant fluctuation in circulating HA not seen in mice, so we
used another mouse model—a liver-specific, doxycycline-
inducible Has2 overexpressing mouse (Liv-Has2)—to under-
stand the relationship between circulating HA and systemic
glucose homeostasis (Fig. 6A). There is a dose-dependent effect of
doxycycline on circulating HA levels after 5 days of diet treatment
in this mouse model (Supplementary Fig. 5A). Higher doxycy-
cline doses (200 mg/kg or 600 mg/kg in the diet) lead to the death
of the mice within 3 days. We selected an HFHS diet containing
10 mg/kg doxycycline (Dox10 HFHS) as the dose for the sub-
sequent metabolic characterization (Supplementary Fig. 5A).
Gene expression analysis revealed a more than 7-fold increase in
hepatic Has2 expression (Fig. 6B) and 45% increase in serum HA
levels (Fig. 6C). This increase of serum HA is on par with what
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can be obtained in Apn-Has2 animals on Dox600 diets. A 5-day
metabolic cage experiment, with diet treatment started after the
metabolic cage study was initiated, showed no effects due to
elevated circulating HA levels on body weight or body compo-
sition (Supplementary Fig. 5B). Food intake and water con-
sumption did not differ either (Supplementary Fig. 5C). VO2 and
VCO2 were not different (Supplementary Fig. 5D), nor were
respiratory exchange ratios (RER) or heat production in Liv-Has2
mice (Fig. 6D). After 8 weeks of Dox10 HFHS treatment, the mice
had gained similar amounts of weight (Fig. 6E) and displayed the
same level of glucose tolerance (Fig. 6F); none of the serum lipid
profiles measured were different (Fig. 6G); hepatic function was
not compromised, as indicated by unaltered AST and ALT levels
(Fig. 6H).
When the doxycycline dose was raised to 50 mg/kg (Dox50),
the circulating HA levels were further increased to two-fold above
the levels of the control mice (Supplementary Fig. 5A). After a 4-
week Dox50 HFHS treatment, mice gained less weight (Supple-
mentary Fig. 5E), but serum lipids profiles and glucose tolerance
remained the same (Supplementary Fig. 5F, G). With the liver
AST and ALT levels trending up, together with a lethal phenotype
of Liv-Has2 mice on Dox200 diet, these data suggest potential
liver toxicity upon higher level Has2 overexpression in the liver
(Supplementary Fig. 5H).
Cellular Has2 overexpression primes cells for lipolysis. Adipose
tissue Has2 overexpression leads to a cellular morphology with
multilocular lipid droplets in adipocytes (Fig. 3E). When mice
were exposed to 16 weeks of HFHS feeding, the adipocytes
appeared significantly smaller (Fig. 4J), consistent with a role of
Has2 expression in adipocyte lipid metabolism. To further
understand how Has2 affects adipocyte lipid metabolism, addi-
tional cohorts of Apn-Has2 mice were assayed (Fig. 7A). After an
oral gavage of intralipid, Apn-Has2 mice pre-fed 7 weeks of
Dox600 HFHS showed higher plasma triglycerides (Fig. 7B).
Given that Has2 overexpression is specific to the adipocytes, the
intestinal lipid absorption is expected to be the same. A higher
plasma triglyceride indicates an impaired clearance of circulating
triglyceride in those mice. When Apn-Has2 mice were challenged
with CL316,243, a β3-adrenergic receptor agonist, they had more
glycerol in circulation despite the same basal glycerol levels
(Fig. 7C). Enhanced glycerol release upon CL316,243 treatment
was also seen in in vitro differentiated adipocytes treated with
high molecular weight HA (Fig. 7D). Despite the lack of a dif-
ference in circulating triglycerides or NEFA levels in Apn-Has2
mice on both normal diet and HFHS diets (Supplementary
Fig. 6A), free-glycerol levels from inguinal and epididymal fat
depots of Apn-Has2 mice were much higher (Fig. 7E). This also
leads to higher fasting serum glycerol (Fig. 7F). The Apn-Has2
inguinal depots also had higher levels of Aqp3 and Aqp9 tran-
scripts, each encoding a water/glycerol transporter (Supplemen-
tary Fig. 6B). Expression of Swell1, a cellular volume sensor on the
plasma membrane, is also increased in Apn-Has2 inguinal depots
(Supplementary Fig. 6B). Altogether these data indicate that
adipose tissue Has2 overexpression prompts adipocytes to gen-
erate more free glycerol, which is readily released upon stimula-
tion and may inhibit clearance of triglyceride from the
circulation.
However, Apn-Has2 inguinal adipose tissue shows a decreased
expression of lipolysis related genes (Fig. 7G) and reduced
amounts of total HSL protein when normalized to α-Tubulin
(Fig. 7H). Despite the enhanced lipolysis upon challenges like
fasting, CL316,243 treatment or cold exposure, the livers of Apn-
Has2 mice displayed lower triglyceride content in both the fasting
and the fed state (Fig. 4K), suggesting that the FFAs released from
adipocytes due to enhanced adipose tissue lipolysis are effectively
metabolized by the liver. Livers from mice treated for four weeks
with HA showed an increase in ketone bodies (Supplementary
Fig. 6C), reflecting an increase in hepatic fatty acid oxidation in
response to elevated circulating HA.
Similarly, hepatic Has2 overexpression led to reduced hepatic
triglyceride content on HFHS diets (Supplementary Fig. 6D, E)
despite an absence of any improvements in glucose tolerance,
further indicating a role of HA in mobilizing lipid droplets.
Discussion
An increase in HA has been implicated in the etiology of both
Type 17 and Type 2 diabetes11, and reducing HA by 4-MU
treatment7,27 or administration of PEG-PH2011 were reported to
exert beneficial effects, pointing to a pathological role of HA in
developing both types of diabetes. However, as a natural phe-
nomenon, naked mole-rats produce a much higher level of HA
than laboratory rats, but live an extraordinarily long life without
known metabolic abnormalities28,29. In the study reported here,
Fig. 4 Adipose tissue Has2 overexpression improves glucose tolerance on HFHS. A Schematic representation of Apn-Has2 mouse treatment for panels
B–L. Multiple cohorts of mice were used. B Relative body weights of Apn-Has2 animals on Dox600 HFHS diet (n= 9 mice per each genotype for period
0–6 weeks, n= 6 mice per each genotype for body weight measured at 16 weeks). Two-way ANOVA followed by Sidak’s multiple comparisons test,
adjusted p-value > 0.9999, 0.6705, 0.2137, 0.1131, <0.0001 for 0, 2, 4, 6, 16 weeks, respectively. C Fat mass and lean mass of Apn-Has2 mice 7 weeks on
Dox600 HFHS diet (n= 9 mice per each genotype). Two-tailed t-test. D RER and heat production of Apn-Has2 mice measured in metabolic cages. Cage
temperature was reduced from 23 degree to 6 degree in the middle of the third night. Heat production in control and Apn-Has2 mice after temperature
change was analyzed using two-way ANOVA. (n= 8 mice per each genotype). Two-way ANOVA test for time points after ramping to 6 °C (time points
66-75), p= 0.0008 for genotype factor, p= 0.0084 for time factor. E Glucose tolerance in Apn-Has2 mice. (n= 10 mice for control, n= 8 mice for Apn-
Has2). Two-way ANOVA followed by Sidak’s multiple comparisons test, adjusted p-value= 0.9994, 0.0174, 0.0014, 0.2834, 0.8711 for 0, 15, 30, 60, and
120min, respectively. AUC was analyzed by two-tailed t-test, p= 0.0252. F 2-DG uptake in inguinal, epididymal adipose tissues (AT), and gastrocnemius
and soleus muscles. (n= 5 mice for control, n= 6 mice for Apn-Has2). Two-tailed t-test, p= 0.0099, 0.0899, 0.7387, 0.3488, for inguinal, epididymal
adipose tissues (AT), and gastrocnemius and soleus muscles, respectively. G Insulin-stimulated 2-DG uptake in differentiated adipocytes derived from SVF
isolated from apn-Has2 transgenic mice (n= 3 wells). Two-way ANOVA test, p < 0.0001 for treatment factor, p= 0.016 for genotype factor. Ctrl vs. Apn-
Has2, p= 0.9995 (no insulin) and 0.0054 (10 nM insulin) for post-hoc Sidak’s multiple comparisons test. H Insulin tolerance in Apn-Has2mice (n= 3 mice
for control, n= 4 mice for Apn-Has2). Two-way ANOVA test. I Pyruvate tolerance in Apn-Has2 mice (n= 8 mice for control, n= 7 for Apn-Has2). Two-
way ANOVA test. J Representative histology of inguinal adipose tissue (upper panels) and liver (lower panels) from Apn-Has2 mice after 16 weeks
Dox600 HFHS diet treatment. Scale bar= 100 µm. K Quantification of liver triglyceride from Apn-Has2 mice under fast or fed conditions after 16 weeks
Dox600 HFHS diet treatment. (Under fasting condition: n= 11 mice for control, n= 5 mice for Apn-Has2; under fed condition: n= 5 mice for control, n= 6
mice for Apn-Has2). Two-tailed t-test, p= 0.0286, and 0.0481 for fast and fed conditions, respectively. L Fasting insulin, fasting glucose, and HOMA-IR of
Apn-Has2 mice after 16 weeks Dox600 HFHS diet treatment. (n= 6 mice per genotype). Two-tailed t-test, p < 0.0001, =0.3828, and 0.0003 for fasting
serum insulin, fasting glucose, and HOMA-IR, respectively. All data are presented as mean ± s.e.m. *indicates p≤ 0.05, **indicates p≤ 0.01.
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we indeed observed an inverse correlation between circulating
HA levels and overall metabolic fitness. However, to our surprise,
several lines of evidence point to a beneficial effect of HA,
especially in the adipose tissue. Whole-body Has2 overexpression
improves glucose tolerance, and this improvement is recapitu-
lated with just adipose tissue Has2 overexpression. Furthermore,
we excluded the possibility of circulating HA as the major con-
tributor of improved glucose tolerance.
A lot of interest has been centered around the use of 4-MU as
an inhibitor of HA production to treat metabolic diseases. The
excitement is partially due to the fact that 4-MU has been
approved for clinical use in many countries as an over-the-
counter choleretic and antispasmodic medication with a great
safety profile. The compound has been demonstrated to improve
the thermogenic capacity of brown adipose tissue27. However, our
results raise the question whether 4-MU truly inhibits HA
synthesis in adipose tissue, and where the metabolic benefits of
long-term high-dose 4-MU treatment originate from. Firstly, in
rodents, previous studies have demonstrated that the extraction
rate of 4-MU by the gastrointestinal system to be around ~40%
and by the liver to be almost ~100%30, suggesting the fraction of
an oral administered 4-MU that reaches the systemic circulation
as the original compound is very low. This pattern agrees with
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Fig. 5 Effects of HA i.p. injections on glucose metabolism. A Schematic representation of mouse treatment for panels B–D. B Serum HA levels after an HA
i.p. injection (n= 6 mice per group). Two-way ANOVA followed by Sidak’s multiple comparisons test, adjusted p-value= 0.8642, <0.0001, <0.0001 for
-4 h, 0, and 15 min, respectively. C Oral glucose tolerance test 4 h after an HA i.p. injection (n= 12 mice per group). D Serum insulin levels assayed at times
indicated by blue arrows in panel A (n= 12 mice per group). E Schematic representation of mouse treatment for panels F–I. Two cohorts of mice were
used. F Repeated HA treatment effects on oral glucose tolerance (n= 8 mice per group). Two-way ANOVA followed by Sidak’s multiple comparisons test,
adjusted p-value= 0.9546, 0.9700, 0.0467, 0.4970, 0.9873 for 0, 15, 30, 60, and 120min, respectively. G Serum insulin levels after an oral glucose
challenge (n= 4 mice for PBS, n= 6 mice for HA treatment). H Repeated HA treatment effects on pyruvate tolerance test (n= 8 mice for PBS, n= 9 mice
for HA treatment). I Repeated HA treatment effects on insulin sensitivity. Glucose levels are plotted as the percentage of Time 0 (n= 8 mice). Two-way
ANOVA followed by Sidak’s multiple comparisons test, adjusted p-value= 1, 0.2196, 0.3748, 0.0375, 0.6450 for 0, 15, 30, 60, and 120min, respectively.
All data are presented as mean ± s.e.m. *indicates p≤ 0.05, **indicates p≤ 0.01. Two-way ANOVA (C) (D) (G) (H).
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MU treatment. Decreasing Has2 levels were one of the proposed
mechanisms for 4-MU to inhibit HA production. Lack of changes
in Has2 expression in the adipose tissue also suggests missing 4-
MU actions in the adipose tissue. HFHS diet also did not increase
expression of any of the Has isoforms (Fig. S2A). Secondly, the
typically approved 4-MU dosing regimen for adults is 300–800
mg three times/day by mouth (i.e., 900–2400 mg/day). In con-
trast, the reported dose of 4-MU required in the literature to
achieve a significant reduction in HA levels is much higher24,25.
Mice fed chow containing 5% 4-MU, a dose calculated to deliver
250 mg/mouse/day, translates to 8 g/kg body weight in mice, far
higher than the doses used in human subjects. This high dose of
4-MU treatment can lead to a transient repression of food intake,
which may be the major contributor to the metabolic benefits
seen. 4-MU used at such high doses could also have unfavorable
effects on atherosclerosis24. Thirdly, another suggested major
mechanism for 4-MU to inhibit HA production is via its function
as a competitive substrate for UDP-glucuronosyltransferase
(UGT) to synthesize UDP-N-acetylglucosamine (UDP-GlcNAc),
one of the two substrates for HA synthesis23. UDP-GlcNAc is also
extensively involved in intracellular signaling as a substrate for O-
linked N-acetylglucosamine transferases, and it serves as a sub-
strate for making glycosaminoglycans, proteoglycans, and glyco-
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Fig. 6 Hepatic Has2 overexpression has no effect on glucose tolerance. A Schematic representation of Liv-Has2 mouse treatment for panels B–H.
Multiple cohorts of mice were used. B Has2 gene expression in Liv-Has2 livers on Dox10 HFHS diet for 3 days (n= 6 mice). Two-tailed t-test, p= 0.0013. C
Serum HA for Liv-Has2 mice on Dox10 HFHS diet for 5 days (n= 8 mice). Two-tailed t-test, p= 0.009. D RER and calculated heat production in Liv-Has2
mice during 5-day of Dox10 HFHS diet feeding starting on the day 0 of metabolic cage study (n= 12 mice). E Body weight of Liv-Has2mice before and after
Dox10 HFHS diet for 8 weeks (n= 6 mice for control, n= 7 mice for Liv-Has2). F Glucose tolerance test of Liv-Has2 mice after 8 weeks of Dox10 HFHS
treatment (n= 6 mice for control, n= 7 mice for Liv-Has2). G Serum lipids levels of Liv-Has2 mice after 8 weeks of Dox10 HFHS treatment (n= 13 mice for
control, n= 10 mice for Liv-Has2). H Serum AST and ALT levels of Liv-Has2 mice after 8 weeks of Dox10 HFHS treatment. (n= 13 mice for control, n= 10
mice for Liv-Has2). All data are presented as mean ± s.e.m. **indicates p≤ 0.01. Two-tailed t-test (G) (H); two-way ANOVA (D) (E) (F).
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Fig. 7 Cellular Has2 overexpression primes cells for lipolysis. A Schematic representation of Apn-Has2mouse treatment for panels B–H. Multiple cohorts
of mice were used; CL: CL 316,243. B Intralipid tolerance test for Apn-Has2mice (n= 6 mice per genotype). Two-way ANOVA followed by Sidak’s multiple
comparisons test, adjusted p-value= 0.7001, 0.0002, 0.9997, 1 for 0, 1.5, 3, and 6 h, respectively. C Glycerol release after β3 adrenergic receptor agonist
CL 316,243 treatment (n= 5 mice per group). Two-way ANOVA followed by Sidak’s multiple comparisons test, adjusted p-value= 0.9869, 0.0439,
0.0813, 0.3049 for 0, 15, 30, and 60min, respectively. D Glycerol release from in vitro differentiated adipocytes treated with HMW HA (10 µg/mL, 5 h)
before and with CL 316,243 (1 µM) stimulation for 2 h (n= 4 mice per group). Two-way ANOVA followed by Sidak’s multiple comparisons test, adjusted p-
value= 0.9749, 0.0125 for Vehicle vs. HA treatment before CL and after CL, respectively. E Tissue glycerol levels in Apn-Has2 mice (n= 16 mice for
control, n= 11 mice for Apn-Has2). Two-tailed t-test, p= 0.0187, <0.0001 for Subcutaneous and Epididymal depot, respectively. F Serum glycerol of Apn-
Has2mice after overnight fasting (n= 5 mice for control, n= 3 mice for Apn-Has2). Two-tailed t-test, p= 0.0266. G Expression of lipolysis related genes in
inguinal adipose tissue from mice treated with 5 days of Dox600 chow diet (n= 8 mice for control, n= 12 mice for Apn-Has2). Multiple two-tailed t-test, p
= 0.0053, 0.0024, 0.00003, 0.00008, 0.014, 0.002 for Adrb1, Adrb2, Adrb3, Pde3b, Pnpla2, Lipe, respectively. H Western blot of HSL protein. Tissue
lysates were prepared from the white adipose tissue dissected from mice treated with 9 weeks of Dox600 HFHS diet. HSL and Tubulin were blotted on two
membranes in parallel. Densitometry result of HSL signal normalized to α-Tubulin is shown on the right (n= 3 mice per genotype). Two-tailed t-test, p=
0.10. All data are presented as mean ± s.e.m. *indicates p≤ 0.05, **indicates p≤ 0.01.
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of cellular targets. Lastly, numerous reports have suggested a
beneficial effect of HA in longevity28, joint health13,14 and pro-
tection from a septic response to LPS32 and colitis33. HAS2
deficiency (reported only in a single person) leads to cardiac
pathology, whereas a complete deficiency of Has2 in mice causes
embryonic lethality due to cardiac defects34, highlighting the
importance of HA production in additional physiological pro-
cesses not conventionally examined. HA is also essential for
surfactant protein C-positive alveolar progenitor cell renewal35
and the maintenance of the endothelial glycocalyx24,36. All these
observations strongly argue against using systemic inhibition of
HA production to treat metabolic diseases. Despite those argu-
ments, our study does not dispute the potential use of 4-MU for
other diseases. Strategies taking advantage of the pharmacology of
4-MU of limited tissue exposure to target abnormal HA levels in
the gastrointestinal track and the liver may still be viable
therapeutic areas.
The beneficial effects of adipose tissue HA production on
systemic glucose metabolism is likely multifactorial: using glucose
to synthesize HA that then spills into circulation may dissipate a
small amount of energy. It also reduces glucose uptake and
primes adipocytes for lipolysis, preventing adipocytes from stor-
ing an excess amount of energy. This leads to reduced adipocyte
size and improved overall metabolic health when other organs,
including the liver, adapt and effectively handle excessive lipids
that are conventionally handled by adipocytes. An increase in
circulating ketone bodies after HA treatment suggests increased
fatty acid oxidation and thus supports this hypothesis. Another
possibility is that HA production in adipose tissue promotes
beneficial remodeling, allowing enhanced secretion of favorable
adipokines to communicate with other organs, such as the liver,
to reduce gluconeogenesis.
A recent report described a self-assembled hyaluronic acid
nanoparticle to be preferentially targeted to the adipose tissue,
modulating adipose tissue inflammation, and alleviating insulin
resistance37. This is consistent with our observations of beneficial
effects of HA on adipose tissue proper. Whether inflammation
plays a major role in our models will need to be investigated in
future studies.
HA synthesis substrates GlcUA and GlcNAc are derived from
glucose, and HA production in differentiated 3T3-L1 adipocytes
is increased by high-glucose medium38, suggesting high circu-
lating glucose levels in diabetes may lead to a systemic increase in
HA levels. However, despite increased serum HA, adipose tissue
from those obese mice showed a significant decrease in HA
content (Supplementary Fig. 7A, B). This agrees with the lack of
increase in adipose tissue Has1, Has2, Has3 expression after
HFHS diet treatment. Similarly, a disconnect of blood glucose
levels and tissue HA levels was seen in Type 1 diabetes, pro-
moting authors to suspect inflammation rather than glucose
drives HA levels in diabetes8.
One interesting observation is the link between HA production
and cellular lipolysis. We believe osmotic pressure may be the link
between two phenomena, as indicated by changes in the cellular
volume sensor Swell139 upon Has2 overexpression in adipocytes.
We have discussed previously in a review38 that if the con-
centration of HA increases by two-fold, the osmotic pressure will
increase by more than a four-fold. The osmotic pressure can be
further increased if HA is connected to collagen, which is the case
in WAT, where the pericellular HA is connected with Col VI. To
counter the increased osmotic pressure, cells can accumulate
polyols40, which, in the case of adipocytes, are represented by
glycerol. The glycerol can be derived from lipolysis or de novo
synthesis. However, the expression of several key enzymes in
lipolysis was reduced, and HSL protein levels were also reduced in
Apn-Has2 adipose tissue, suggesting a mechanism independent of
HSL in linking osmotic pressure to cellular glycerol accumulation.
One limitation of the study is that we could not systemically
evaluate the size distribution of HA in all different models and
different tissues. Size-dependent differences in hyaluronan sig-
naling and downstream biological effects are well established41.
However, it is inherently low-throughput and technically chal-
lenging to separate HA by molecular weight.
In summary, HA is a naturally occurring, critical component of
the extracellular matrix. It displays great variation of abundance
in different tissues, highlighting probable diverse functions in
these tissues. HA in adipose tissue governs its biology and phy-
siology, fundamentally linked to glucose and lipid metabolism.
Strategies to target HA abundance and metabolism should have a
global view and balance the benefit against adverse effects on
other organs. Future work will need to look into the role of HA
on other aspects of adipose tissue physiology, such as inflam-
mation and adipogenesis. Determination of adipose tissue HA
sizes under metabolic stress will also significantly deepen our
understanding of the HA, as HA of different molecular weights
likely engage distinct signaling events and play different roles.
Methods
Animals. Animals were cared and used in accordance with the United States
Animal Welfare Act and experimental protocols were approved by the Institutional
Animal Care and Use Committee of the University of Texas Southwestern Medical
Center (UTSW) and Baylor College of Medicine. Adiponectin-rtTA mice were
previously generated and verified in the lab26. TRE-Has2 mice were generated by
subcloning the mouse Has2 gene into the pTRE vector (Clontech) with a rabbit β-
globin 3’ UTR42. Systemic expressed R26-M2rtTA (The Jackson Laboratory, B6.
Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J, Strain: 006965), liver-specific albumin-
Cre transgenic (The Jackson Laboratory, B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J,
Stock No: 003574) and Rosa26-loxP-STOP-loxP-rtTA transgenic (The Jackson
Laboratory, Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J, Stock No: 005572) mice were
purchased from Jackson Laboratories. High-fat high-sucrose (HFHS) diet (S1850),
HFHS containing doxycycline 10 mg/kg (S7341), 50 mg/kg (S7624) or 600 mg/kg
(S7067) were purchased from Bio-Serv. 4-Methylumbelliferone (4-MU) was pur-
chased from Sigma (M1381) and blended into HFHS diet in house at the indicated
concentrations. Hyaluronic acid sodium salt from rooster comb (Sigma Aldrich,
Ca. Number: H5388) was dissolved in sterile saline and administered to mice by
indicated routes. All treatments were started at 8-10 weeks of age. Only male mice
were used. Serum HA levels were measured using an ELISA kit (R&D systems, Cat.
Number: DHYAL0) using manufacturer provided protocol, which detects all HA
with a molecular weight higher than 35 KDa. Body composition was determined by
quantitative magnetic resonance. Mice were randomly allocated to experimental
groups, were weight-matched at the beginning of experimental protocols. Inves-
tigators were not blinded to treatment groups during studies.
Studies conducted in human subjects. A total of 30 males and females with
obesity participated in this study, which was conducted in the Clinical Transla-
tional Research Unit (CTRU) at Washington University School of Medicine in St.
Louis, MO. All subjects completed a screening history and physical examination,
standard blood tests and an75 g oral glucose tolerance test. Written informed
consent was obtained from all subjects before their participation in this study,
which was approved by the Institutional Review Board of Washington University
School of Medicine in St. Louis, MO and registered in Clinical Trials.gov
(NCT02706262). Participants were separated into two distinct groups: (i) obese
with normal oral glucose tolerance (Obese-normal) (fasting plasma glucose con-
centration <100 mg/dL, 2-h OGTT plasma glucose concentration <140 mg/dL and
HbA1c ≤5.6%); and (ii) obese with prediabetes (Obese-prediabetes) (fasting plasma
glucose concentration ≥100 mg/dL 2-h OGTT plasma glucose concentration ≥140
mg/dL, and/or HbA1c ≥5.7%). On a separate occasion, subjects were admitted to
the CTRU at 17:00 h on day 1 and consumed a standard meal between 18:00 h and
19:00 h. At 06:30 h the next morning on day 2, a catheter was inserted into an
antecubital vein for serial blood sampling. At 07:00 h a meal was provided con-
taining one-third of the participant’s energy requirements17 and was comprised of
50% carbohydrate, 35% fat, and 15% protein. Blood samples were obtained before
and serially for 5 h after ingesting a mixed meal ingestion.
Metabolic phenotyping. Glucose tolerance test (GTT), pyruvate tolerance test
(PTT), insulin tolerance test (ITT) and Intralipid tolerance test were performed as
previously described43–46. Serum insulin levels were measured using ALPCO
Mouse Insulin ELISA Jumbo kit (Cat. Number: 80-INSMS-E10). β3 adrenergic
receptor agonist CL 316,243 (Sigma, Ca. Number: C5976) was used at 1 mg/kg
body weight through intraperitoneal injection, CL 316,243-stimulated glycerol
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release was performed as previously described44. Liver triglyceride extraction and
quantification was performed at UTSW metabolic phenotyping core using a pre-
viously published protocol43. Serum parameters (aspartate transaminase, alanine
transaminase, cholesterol, triglyceride, very low-density lipoprotein, low-density
protein and direct high density lipoprotein) were measured and calculated with a
VITROS analyzer (Ortho Clinical Diagnostics) at UTSW metabolic
phenotyping core.
Quantitative RT- qPCR. RNA was isolated from frozen tissues by homogenization
in Trizol Reagent (Invitrogen) with the manufacturer provided protocol47. One
microgram of RNA was used to transcribe cDNA using a reverse transcription kit
(Bio-rad). RT–qPCR primers are obtained from Harvard PrimerBank48 and listed
in Supplementary Table 1. The messenger RNA levels were calculated using the
comparative threshold cycle (Ct) method, normalized to gene Rps16 or Rps18.
Western blotting. Protein extractions were performed as previously described44,49.
Primary antibodies HAS2 (Santa Cruz Biotechnology, sc-34068) (1:200 dilution),
HSL (Santa Cruz Biotechnology, sc-74489) (1:200 dilution), α Tubulin (Santa Cruz
Biotechnology, sc-53030) (1:200 dilution), Actin (Sigma #A4700) (1:1000 dilution),
Adiponectin (homemade) (1:1000 dilution) were used. Protein abundance was
detected using the one of the following secondary antibodies: Goat anti-Mouse
IRDye 680RD (Li-cor 926-68070), Goat anti-rabbit IRDye 800CW (Li-cor 925-
32211) or Goat anti-Rat DyLight 800 (Thermo Fisher SA5-10024) at 1:10,000
dilutions. Antibody decorated membranes were then visualized on a Li-Cor
Odyssey infrared scanner (Li-Cor Bioscience). The scanned data were analyzed
using Odyssey Version 3.0 software (Li-Cor Bioscience).
2-deoxyglucose (2-DG) uptake in animals. C14 labeled 2-deoxyglucose (13 (μCi/
mouse) was administered after a 6-h fast by tail-vein injection. After 25 min, tissues
were rapidly dissected and frozen. The uptake of 2-deoxyglucose was calculated as
previously described50.
Insulin-stimulated 2-deoxyglucose (2-DG) uptake in differentiated adipo-
cytes. Insulin-stimulated 2-DG uptake assays were performed in triplicate in 12-
well culture plates modified from previous publications47,51. In brief, SVF was
isolated, cultured and differentiated as described previously52. In all, 0.5 µg/mL
doxycycline was added 1 day before to induce transgene expression. Differentiated
adipocytes with transgene induction were conditioned in differentiation medium
without insulin and doxycycline overnight before being fasted for 40 min in
DMEM/F12 no glucose medium supplemented with 1 mg/mL BSA and 1mM
pyruvate. Glucose uptake was performed by adding 2-[1,2-3 H]-deoxy-D-glucose
in the presence of 0 and 10 nM insulin. Relative uptake is calculated by quantifying
the radioactivity of 2-[1,2-3 H]-deoxy-D-glucose-6-phosphate.
Histology and imaging. Adipose tissue and livers were excised and fixed overnight
in 10% PBS-buffered formalin and were thereafter stored in 50% ethanol. Tissues
were sectioned (5 µm), rehydrated and stained at Pathology Core at UT South-
western. Microscopic images were taken on a Keyence BZ-X710 imaging system.
Flow cytometry. Minced Inguinal fat depots were digested for 2 h while shaking at
37 °C in buffer containing 100 mM HEPES (pH 7.4), 120 mM NaCl, 50 mM KCl, 5
mM glucose, 1 m CaCl2, 1.5% BSA, and 1 mg/mL collagenase D (Roche
11088882001). Digested tissues were then filtered through a 100 µm cell strainer
and then centrifuged for 5 min at 600 × g to pellet the stromal vascular fraction
(SVF) cells. Red blood cells were lysed using commercial lysis buffer (Sigma
R7757). 1 × 106 SVF cells were first incubated on ice for 20 min in 200 µl of 2%
FBS/PBS containing anti-mouse CD16/CD32 Fc block (clone 2.4G2) at a dilution
1:200. Cells were then incubated with primary antibody (PE anti-CD31 clone 390
1:200; PE anti-CD45 clone 30-F11 1:200 and APC anti-CD140B clone APB5 3:200)
and rotated at 4 °C for 30 min in the dark. Cells were then washed three times with
2% FBS/PBS at 600 × g for 5 min. Cells were analyzed using a FACS CantoIITM
flow cytometer (UT Southwestern Medical Center Flow Cytometry Core Facility).
Flow cytometry plots were generated with FlowJo Version 10.2. All antibodies were
obtained commercially from BioLegend (San Diego, CA USA).
For analysis, cells were initially selected by size, on the basis of forward scatter
(FSC) and side scatter (SSC). SV cells isolated from wild-type mice, along with
fluorescent-minus-one (FMO) controls, were used to determine background
fluorescence levels. The populations were gated on PE (CD31 and CD45) and APC
(CD140B) channels. Percentages of Pdgfrβ+/Lin- cells were obtained from control
and transgenic samples and quantified.
HA extraction for ELISA. The procedure was performed as previously described28,
extracted HA was quantified using an ELISA kit (R&D systems, Cat. Number:
DHYAL0). The tissue HA content is normalized to the wet weight used for
extraction.
HA molecular weight (MW) electrophoresis. The procedure was performed as
previously described with some modifications53,54. Following dissection of fat tis-
sues and measuring wet weight, fat tissues were digested in 100 mM ammonium
acetate with 0.0005% phenol red (pH 7.0) containing 0.25 mg/mL proteinase-K
(Roche) for 4 h at 60 °C. Proteinase-K was inactivated by boiling, and undigested
tissues were pelleted by centrifugation. An aliquot of 20 μL supernatant equal to
100 mg wet weight was then treated with 1 μL of deoxyribonuclease (Ambion,
Austin, TX) and 1 μL of ribonuclease (Roche) for 2 h at 37 °C. Samples were boiled
to inactivate enzymes, and were precipitated in 80% ethanol at −20 °C overnight.
After centrifugation at 13,000 × g, pellets were resuspended in 20 μL of Tris-Na
Acetate-EDTA (pH.7.9) and 3 μL loading buffer (0.2% Bromophenol Blue, 1 mL
TAE buffer, and 8.5 mL glycerol). Samples were run on a 1% agarose gel (Seakem
HGT; Cambrex, Rockland, ME) made in TAE buffer. The gel was pre-run for
approximately 1 h at 100 V before loading samples and HA size standards (Hya-
lose, Oklahoma City, OK). After electrophoresis at 100 V, the gel was incubated in
water with gentle shaking for 1 h, followed by incubation in Stains-All solution 2.5
mg/mL (Sigma) of 30% ethanol overnight in the dark. Gel was destained in water
until bands were visualized before scanning.
Adipocyte culture and CL 316,243 treatment. SVF was isolated, cultured and
differentiated as described previously52. Culture medium with 10 µg/mL HA was
added, 5 h after the treatment, culture medium was sampled, and refreshed with
new medium containing 1 µM of CL 316,243, culture medium was sampled again,
and cells were lysed to measure protein content. Cellular glycerol release was
calculated by subtracting beginning medium glycerol content from the end glycerol
content, and was normalized to the protein content.
Free-glycerol extraction. Frozen accurately weighed adipose tissue samples (200
mg) were homogenized in 1 mL of MeOH in borosilicate glass tubes using a
mechanical homogenizer. The homogenizer probe was rinsed with 1 mL of MeOH
and the methanolic extracts were combined. 4 mL of Hexane was added to the
methanolic homogenate, then samples were thoroughly vortexed for 30 s. Samples
were then centrifuged in a bucket benchtop centrifuge at 2500 × g for 10 min. The
hexane top layer was discarded and the methanolic bottom layer was re-extracted
with additional 4 mL of hexane. The final bottom methanolic layer was dried under
purified nitrogen stream without heat. Samples were reconstituted in 200 µL of
ultrapure water. Twenty microliters of sample were used for analysis using the free-
glycerol reagent from Sigma Aldrich (Catalog Number F6428).
Metabolic cage experiment. Metabolic cage studies were conducted using a
PhenoMaster System (TSE systems) at UTSW metabolic phenotyping core as
previously described55. Mice were acclimated in temporary holding cages for 5 days
before recording. Food intake, movement, and CO2 and O2 levels were measured at
various intervals (determined by collectively how many cages were running con-
currently) for the indicated period shown on figures.
Statistics and reproducibility. All values are expressed as the mean ± s.e.m.
*indicates p ≤ 0.05, **indicates p ≤ 0.01, unless the values were explicitly labeled on
the graph. Micrographs in Figs. 2e; 3c, e; 4j and Supplementary Figs. 3h; 6d were a
representative from at least three experiments.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All other relevant data are available from the corresponding authors upon reasonable
request.
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